Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$76.94Price
Low $109.15
Mid $139.77
High $170.49
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.
Intangible assets via unmatched patent
Intangible assets via unmatched patent portfolio and brand loyalty.
High switching costs for veterinary
High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
Cycle upside
Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.
Each scenario for ZTS (ZTS) carries a five-year price target, an explicit set of assumptions (growth, terminal multiple, margin path), and a probability weight calibrated against current visibility.
Probability weights start from a 25/50/25 default and are asymmetry-adjusted: when downside risk is elevated, base + bear gain weight; when visibility is high (long RPO, multi-year contracts), bull and base both gain.
Expected return is the probability-weighted average of the three scenario returns. The expected-value table reports the weighted price, weighted return, and asymmetry to help the reader compare risk-reward against the rating band.
When our composite fair value differs from private calibration references by more than 30%, the calibration-divergence diagnostic is run to identify which assumptions drive the gap; the result is summarised in the parent valuation surface.
FAQ
ZTS — frequently asked questions
Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Our composite fair-value range for ZTS is $109–$170, with a midpoint of $140. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ZTS's archetype.
Our current rating for ZTS is Strong Buy with a confidence score of 88/100. Strong Buy. Zoetis represents an extreme value dislocation for a premier mature compounder. The $139.77 composite fair value provides massive upside against irrational market pessimism. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ZTS are: Margin Contraction; Livestock Headwinds; Macro Demand Shock. The single biggest risk is Margin Contraction: Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.
Our current rating for ZTS is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($109–$170) versus the current price of $76.9.
ZTS is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ZTS.